{"id":"W2334651034","doi":"10.1186/s12967-016-0836-6","title":"A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies","year":2016,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Prostate Cancer Fight Foundation; Institute of Cancer Research; Ontario Institute for Cancer Research; Roche Canada","keywords":"Rosuvastatin; Medicine; Erlotinib; Toxicity; Dosing; Pharmacology; Pharmacokinetics; Rosuvastatin Calcium; Internal medicine; Maximum tolerated dose; Oncology; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002566311,0.0001358906,0.0003766265,0.0001212417,0.00002189933,0.000002574062,0.00009907389,0.00003646703,0.00003136959],"category_scores_gemma":[0.00005535762,0.00007056406,0.00003433396,0.0001176752,0.0001143765,0.00001805597,0.000006137066,0.00007256587,1.317936e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001581143,"about_ca_system_score_gemma":0.000194196,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001453737,"about_ca_topic_score_gemma":0.0001375051,"domain_scores_codex":[0.9986166,0.00005142744,0.0005151311,0.0001467555,0.0005298573,0.0001401743],"domain_scores_gemma":[0.9989148,0.00003633159,0.000369325,0.0001223556,0.0004726805,0.00008452187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.1451991,0.007905019,0.2126553,0.0001497527,0.0009707343,0.00001203463,0.007233349,0.002111133,0.464726,0.0001690716,0.002361052,0.1565074],"study_design_scores_gemma":[0.2517613,0.06504191,0.6532236,0.00117647,0.0002978086,0.00003467391,0.001259738,0.000003160711,0.01123955,0.0001730843,0.01541617,0.0003725057],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957342,0.0004846351,0.002401937,0.0004640308,0.000533663,0.0002970342,0.00006378681,0.000001648667,0.00001908459],"genre_scores_gemma":[0.9975523,0.00009603846,0.001143797,0.00004894221,0.001085687,0.000006522132,0.00001556938,0.0000153658,0.00003572154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4534864,"threshold_uncertainty_score":0.2877519,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008118803149594204,"score_gpt":0.2767590504885937,"score_spread":0.2686402473389995,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}